We look forward to attending the SAPA-NE 28th Annual Conference on June 13th in Cambridge, MA. The event will feature panel discussions and poster sessions, with the main theme being AI and its impact across the entire drug development cycle. Join us, along with 400+ biopharma leaders, for a packed day of learning and networking!
What is SAPA-NE?
Founded in 1998, the Sino-American Pharmaceutical Professionals Association-New England/Boston (SAPA-NE) is a not-for-profit organization focused on advancing pharmaceutical science and biotechnology. Led by passionate experts, they support scientific research and exchanges through collaborations and annual events.
Event Overview
Date: June 13th, 2026
Venue: Boston Marriott Cambridge, 50 Broadway, Cambridge, MA 02142
Event Schedule
For more information, please refer to the SAPA-NE website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of drug research and development together, see you in Cambridge, MA!
